Timunox increases resistance to the challenge with a low number of cells from Yoshida ascites tumor.
Licastro
G
G
Istituto Policattedra di Patologia Generale, Università di Messina, Italy.
Bottari
C
C
Cavallaro
A
A
Ainis
T
T
Fimiani
V
V
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D051381:Rats; D017207:Rats, Sprague-Dawley; D012517:Sarcoma, Yoshida / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D016305:Thymopentin / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D016305:Thymopentin